Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Biotech company Pharming Group has appointed Sijmen de Vries as its new CEO. Dr de Vries will take up his position as of November 3, 2008 as successor to Francis Pinto who will retire in 2009. Until then, Dr Pinto will stay on as non-executive chairman of the management board to ensure a smooth transition.
Subscribe to our email newsletter
Dr de Vries joins Pharming from Swiss-based 4-Antibody where he was CEO. Dr de Vries has also been CEO of Morphochem and prior to this spent many years at Novartis and at SmithKline Beecham Pharmaceuticals where he held senior business and commercial positions. Dr de Vries also holds non-executive directorships in two private life science companies.
Jaap Blaak, chairman of Pharming’s board of supervisory directors, said: “We are very pleased that the shareholders have agreed to the appointment of Dr de Vries for the position of CEO of Pharming. His medical background and strong commercial track record will be a valuable addition to the management of Pharming. Dr de Vries has international business development and strategic marketing experience which will be of utmost importance to us as we focus on the commercialization of our lead products.”